Last reviewed · How we verify
amiodarone beta blocker sotalol
Sotalol is a non-selective beta-blocker with additional Class III antiarrhythmic activity that slows heart rate and prolongs the cardiac action potential to prevent arrhythmias.
Sotalol is a non-selective beta-blocker with additional Class III antiarrhythmic activity that slows heart rate and prolongs the cardiac action potential to prevent arrhythmias. Used for Atrial fibrillation and atrial flutter (maintenance of normal sinus rhythm), Ventricular arrhythmias including life-threatening ventricular tachycardia, Hypertension.
At a glance
| Generic name | amiodarone beta blocker sotalol |
|---|---|
| Sponsor | Connolly, Stuart, M.D. |
| Drug class | Beta-blocker with Class III antiarrhythmic activity |
| Target | Beta-1 and beta-2 adrenergic receptors; potassium channels (IKr) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Sotalol combines beta-adrenergic receptor antagonism (Class II antiarrhythmic effect) with potassium channel blockade that prolongs the QT interval (Class III effect). This dual mechanism reduces heart rate, slows AV nodal conduction, and increases the refractory period of cardiac tissue, making it effective for both rate control and rhythm suppression in atrial fibrillation and ventricular arrhythmias.
Approved indications
- Atrial fibrillation and atrial flutter (maintenance of normal sinus rhythm)
- Ventricular arrhythmias including life-threatening ventricular tachycardia
- Hypertension
Common side effects
- Fatigue
- Dizziness
- Dyspnea
- Bradycardia
- QT prolongation
- Torsades de pointes
- Hypotension
- Nausea
Key clinical trials
- Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (NA)
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation (NA)
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation (PHASE4)
- Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial Fibrillation (NA)
- Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation (NA)
- Initial Management of Patients Receiving a Single Shock (IMPRESS) (NA)
- Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) (PHASE3)
- AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- amiodarone beta blocker sotalol CI brief — competitive landscape report
- amiodarone beta blocker sotalol updates RSS · CI watch RSS
- Connolly, Stuart, M.D. portfolio CI